Insulet (PODD) has just been added to both the Russell 2500 and Russell 2500 Growth indexes, a change that can influence institutional ownership as index funds align their holdings with the new benchmarks.

Insulet’s recent index additions follow a mixed price pattern, with a 7 day share price return of 5.87% and a 30 day share price return of 5.11%. However, the year to date share price return is down 46.15%, while the 1 year total shareholder return is down 49.21%. This indicates that recent momentum has picked up slightly after a weaker longer term record, set against board changes and active options trading around the stock.

If Insulet’s index move has you thinking about where else growth and disruption might show up, this could be a good moment to scan 40 healthcare AI stocks.

With Insulet’s share price down sharply over the past year but trading at a reported discount to some valuation estimates, the key question is whether investors are seeing a genuine opportunity or if the market already reflects future growth.

Most Popular Narrative: 37.2% Undervalued

Compared with Insulet’s last close at $152.35, the most widely followed narrative points to a fair value of $242.43, implying a sizable valuation gap that rests on specific growth and margin expectations.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Want to see what is baked into that kind of growth story? The narrative leans on ambitious revenue expansion, higher profit margins, and a premium future earnings multiple to reach its fair value.

Result: Fair Value of $242.43 (UNDERVALUED)

However, Insulet’s heavy dependence on the Omnipod platform and the ongoing competitive and regulatory pressure in diabetes devices could quickly weaken this growth-focused narrative.

Another View on Insulet’s Valuation

The first narrative leans heavily on discounted cash flows and future earnings for Insulet, but the market is also putting a price on today’s profits. At a P/E of 34.8x, compared with peers at 34.7x and a fair ratio of 30.2x, the stock screens as expensive on this yardstick, which suggests less room for error if profitability or growth expectations slip. Which lens do you think better reflects the risk you are willing to take?

Next Steps

With mixed sentiment around Insulet and its valuation, this is a good time to review the numbers, pressure test the stories, and weigh both the upside and the downside yourself before reacting to headlines. To see how that balance looks in one place, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Insulet?

If Insulet has sharpened your focus, do not stop here. Broaden your watchlist with a few focused stock ideas that could reshape how you think about opportunity.

• Target potential mispricing by reviewing companies identified as 44 high quality undervalued stocks and see where expectations and current prices may not fully line up.
• Strengthen your income stream by assessing stocks in the 10 dividend fortresses and check which payouts align with your risk and return preferences.
• Prioritise resilience first and returns second with the 74 resilient stocks with low risk scores, so you do not overlook companies that could steady your overall portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.